Importance Of Adherence To Bcr-abl Tyrosine-kinase Inhibitors In The Treatment Of Chronic Myeloid Leukemia

dc.creatorde Almeida M.H.
dc.creatorFogliatto L.
dc.creatorCouto D.
dc.date2014
dc.date2015-06-25T17:52:49Z
dc.date2015-11-26T14:19:41Z
dc.date2015-06-25T17:52:49Z
dc.date2015-11-26T14:19:41Z
dc.date.accessioned2018-03-28T21:21:12Z
dc.date.available2018-03-28T21:21:12Z
dc.identifier
dc.identifierRevista Brasileira De Hematologia E Hemoterapia. Sociedade Brasileira De Hematologia E Hemoterapia, v. 36, n. 1, p. 54 - 59, 2014.
dc.identifier15168484
dc.identifier10.5581/1516-8484.20140014
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84897821802&partnerID=40&md5=c4790c149741718902fb6f1adad16668
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/86340
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/86340
dc.identifier2-s2.0-84897821802
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1244019
dc.descriptionTreatment of chronic myeloid leukemia with BCR-ABL tyrosine kinase inhibitors requires full adherence in order to maximize the likelihood of achieving optimal responses, and to minimize healthcare costs. In this article, we review some of the methods available for assessing compliance, the main consequences of nonadherence on treatment outcomes, major factors commonly associated with poor compliance, a few successful measures for improving adherence and the most accepted recommendations for proactively managing adverse events. © 2014 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. All rights reserved.
dc.description36
dc.description1
dc.description54
dc.description59
dc.descriptionCornelison, M., Jabbour, E.J., Welch, M.A., Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: The role of the midlevel practitioner (2012) J Support Oncol, 10 (1), pp. 14-24
dc.descriptionHughes, T.P., Branford, S., Monitoring disease response to tyrosine kinase inhibitor therapy in CML (2009) Hematology Am Soc Hematol Educ Program, pp. 477-487
dc.descriptionQuintas-Cardama, A., Cortes, J.E., Kantarjian, H., Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia (2008) Clin Lymphoma Myeloma, (SUPPL. 3), pp. S82-S88
dc.descriptionBordonaro, S., Raiti, F., Di, M.A., Lopiano, C., Romano, F., Pumo, V., Active home-based cancer treatment (2012) J Multidiscip Healthc, 5, pp. 137-143
dc.descriptionMarin, D., Bazeos, A., Mahon, F.X., Eliasson, L., Milojkovic, D., Bua, M., Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib (2010) J Clin Oncol, 28 (14), pp. 2381-2388
dc.description(2003) Adherence to Long-term Therapies: Evidence For Action [Internet], , http://apps.who.int/iris/bitstream/10665/42682/1/9241545992.pdf, World Health Organization, [cited 2012 Nov 29]. Available from
dc.descriptionNoens, L., van Lierde, M.A., de Bock, R., Verhoef, G., Zachee, P., Berneman, Z., Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study (2009) Blood, 113 (22), pp. 5401-5411
dc.descriptionPartridge, A.H., Avorn, J., Wang, P.S., Winer, E.P., Adherence to therapy with oral antineoplastic agents (2002) J Natl Cancer Inst, 94 (9), pp. 652-661. , Comment in: J Natl Cancer Inst. 2002
dc.description94(21):1652
dc.descriptionauthor reply 1652
dc.descriptionRuddy, K., Mayer, E., Partridge, A., Patient adherence and persistence with oral anticancer treatment (2009) CA Cancer J Clin, 59 (1), pp. 56-66
dc.descriptionWang, P.S., Benner, J.S., Glynn, R.J., Winkelmayer, W.C., Mogun, H., Avorn, J., How well do patients report noncompliance with antihypertensive medications?: A comparison of self-report versus filled prescriptions (2004) Pharmacoepidemiol Drug Saf, 13 (1), pp. 11-19
dc.descriptionOsterberg, L., Blaschke, T., Adherence to medication (2005) N Engl J Med, 353 (5), pp. 487-497. , Comment in: N Engl J Med. 2005;353(18):1972-4
dc.descriptionauthor reply 1972-4
dc.descriptionPullar, T., Kumar, S., Tindall, H., Feely, M., Time to stop counting the tablets? (1989) Clin Pharmacol Ther, 46 (2), pp. 163-168. , Comment in: Clin Pharmacol Ther. 1990
dc.description47(4):547
dc.descriptionRudd, P., Byyny, R.L., Zachary, V., Loverde, M.E., Titus, C., Mitchell, W.D., The natural history of medication compliance in a drug trial: Limitations of pill counts (1989) Clin Pharmacol Ther, 46 (2), pp. 169-176
dc.descriptionIbrahim, A.R., Eliasson, L., Apperley, J.F., Milojkovic, D., Bua, M., Szydlo, R., Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy (2011) Blood, 117 (14), pp. 3733-3736
dc.descriptionGanesan, P., Sagar, T.G., Dubashi, B., Rajendranath, R., Kannan, K., Cyriac, S., Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia (2011) Am J Hematol, 86 (6), pp. 471-474
dc.descriptionYood, M.U., Oliveria, S.A., Cziraky, M., Hirji, I., Hamdan, M., Davis, C., Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia (2012) Curr Med Res Opin, 28 (2), pp. 213-219. , Comment in: Curr Med Res Opin. 2012;28(7):1164
dc.descriptionauthor reply 1164-5
dc.descriptionDarkow, T., Henk, H.J., Thomas, S.K., Feng, W., Baladi, J.F., Goldberg, G.A., Treatment interruptions and nonadherence with imatinib and associated healthcare costs: A retrospective analysis among managed care patients with chronic myelogenous leukaemia (2007) Pharmacoeconomics, 25 (6), pp. 481-496
dc.descriptionWu, E.Q., Johnson, S., Beaulieu, N., Arana, M., Bollu, V., Guo, A., Healthcare resource utilization and costs associated with nonadherence to imatinib treatment in chronic myeloid leukemia patients (2010) Curr Med Res Opin, 26 (1), pp. 61-69
dc.descriptionEliasson, L., Clifford, S., Barber, N., Marin, D., Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed (2011) Leuk Res, 35 (5), pp. 626-630
dc.descriptionKelley, R.K., Venook, A.P., Nonadherence to imatinib during an economic downturn (2010) N Engl J Med, 363 (6), pp. 596-598
dc.descriptionEfficace, F., Baccarani, M., Rosti, G., Cottone, F., Castagnetti, F., Breccia, M., Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: An observational patient-centered outcome study (2012) Br J Cancer, 107 (6), pp. 904-909. , Comment in: Br J Cancer. 2012;107(6):901-3
dc.descriptionJabbour, E., Deininger, M., Hochhaus, A., Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (2011) Leukemia, 25 (2), pp. 201-210
dc.descriptionJonsson, S., Olsson, B., Soderberg, J., Wadenvik, H., Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study (2012) Ann Hematol, 91 (5), pp. 679-685
dc.descriptionMoon, J.H., Sohn, S.K., Kim, S.N., Park, S.Y., Yoon, S.S., Kim, I.H., Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients (2012) Med Oncol, 29 (2), pp. 1179-1185
dc.description(2013) NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®)-Chronic Myelogenous Leukemia, , http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf, The National Comprehensive Cancer Network, Version 2, [Internet]. 2013 [cited 2012 Nov 29] Available from
dc.descriptionRosti, G., Castagnetti, F., Gugliotta, G., Palandri, F., Baccarani, M., Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML (2012) Cancer Treat Rev, 38 (3), pp. 241-248
dc.descriptionGalinsky, I., Buchanan, S., Practical management of dasatinib for maximum patient benefit (2009) Clin J Oncol Nurs, 13 (3), pp. 329-335
dc.languageen
dc.publisherSociedade Brasileira de Hematologia e Hemoterapia
dc.relationRevista Brasileira de Hematologia e Hemoterapia
dc.rightsaberto
dc.sourceScopus
dc.titleImportance Of Adherence To Bcr-abl Tyrosine-kinase Inhibitors In The Treatment Of Chronic Myeloid Leukemia
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución